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ABSTRACT 31 
 32 
Leber hereditary optic neuropathy and autosomal dominant optic atrophy are the two most 33 
common inherited optic neuropathies. The latter has been associated with mutations in the 34 
OPA1 and OPA3 genes. To date, only six families with OPA3-associated dominant optic 35 
atrophy have been reported. In order to identify additional families we performed Sanger 36 
sequencing of the OPA3 gene in 75 unrelated optic neuropathy patients. Affected individuals 37 
from two families were found to harbour the c.313C>G, p.(Gln105Glu) change in 38 
heterozygous state; this genetic defect has been previously reported in four dominant optic 39 
atrophy families. Intra- and inter-familial variability in age of onset and presenting symptoms 40 
was observed. Although dominant OPA3 mutations are typically associated with optic 41 
atrophy and cataracts, the former can be observed in isolation; we report a case with no lens 42 
opacities at age 38. Conversely, it is important to consider OPA3-related disease in 43 
individuals with bilateral infantile onset cataracts and to assess optic nerve health in those 44 
whose vision fail to improve following lens surgery. The papillomacular bundle is primarily 45 
affected and vision is typically worse than 20/40. Notably, we describe one subject who 46 
retained normal acuities into the fifth decade of life. The condition can be associated with 47 
extraocular clinical features: two affected individuals in the present study had sensorineural 48 
hearing loss. The clinical heterogeneity observed in the individuals reported here (all having 49 
the same genetic defect in OPA3) suggests that the molecular pathology of the disorder is 50 
likely to be complex. 51 
 52 
 53 
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INTRODUCTION 60 
 61 
Inherited optic neuropathies are a clinically and genetically heterogenous group of disorders 62 
associated with selective loss of retinal ganglion cells. Clinically, they are characterised by 63 
colour vision deficits, visual field defects and, typically, bilateral, symmetrical and 64 
irreversible visual loss [1]. Mitochondrial dysfunction appears to play a central role in the 65 
pathophysiology of these disorders and inheritance can be mitochondrial [MIM #535000] or 66 
monogenic; autosomal dominant (for example [MIM #165500] and [MIM #165300]), 67 
autosomal recessive (for example [MIM #612989]) and X-linked [MIM %311050] subtypes 68 
have been described. Notably, certain types of inherited optic neuropathy form part of clinical 69 
syndromes that include additional ocular or non-ocular features [2]. 70 
 71 
Defects in the OPA3 gene [MIM *606580] have been previously associated with both 72 
recessive and dominant optic neuropathy. Biallelic OPA3 mutations cause 3-73 
methylglutaconic aciduria type III [MIM #258501], a recessive neuro-ophthalmological 74 
syndrome, most prevalent amongst individuals of Iraqi-Jewish origin and classically 75 
characterized by the following triad: (i) bilateral optic atrophy diagnosed in the first decade of 76 
life; (ii) a movement disorder (ataxia or extrapyramidal dysfunction) of variable severity 77 
beginning in the first or second decade of life; (iii) increased urinary excretion of 3-78 
methylglutaconic acid [3-8]. Disease-causing OPA3 variants inherited in an autosomal 79 
dominant fashion can also cause optic neuropathy. This is often associated with 80 
congenital/infantile lenticular opacities; hearing loss and neurological symptoms can also be 81 
features of the disorder. Autosomal dominant OPA3-related disease is less common than the 82 
recessive form and only six families have been identified to date. The following dominant 83 
disease-associated variants have been reported [NCBI Reference Sequence: NM_025136.3]: 84 
c.277G>A, p.(Gly93Ser); c.313C>G, p.(Gln105Glu) (recurrent mutation); 85 
c.10_11insCGCCCG, p.(Val3_Gly4insAlaPro) [9,10]. 86 
 87 
The OPA3 gene is composed of at least 3 exons that are alternatively spliced to produce two 88 
major transcripts: OPA3A (exon 1 plus exon 2a; encodes the 179 amino acid isoform b; NCBI 89 
Reference Sequence: NM_025136.3) and OPA3B (exon 1 plus exon2b; encodes the 180 90 
amino acid isoform a; NCBI Reference Sequence: NM_001017989.2). Although cDNA 91 
studies indicate ubiquitous expression of both transcripts, OPA3A is much more strongly 92 
expressed in most tissues, including the brain [11]. Notably, the OPA3A amino acid sequence 93 
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appears to be more conserved in evolution and yet no human disease has been associated with 94 
mutations in the OPA3B-specific exon 2b [7,11]. At the subcellular level, OPA3 localises 95 
predominantly to the mitochondrial inner membrane and although its function remains 96 
unclear previous studies have suggested involvement in the regulation of mitochondrial 97 
morphology [10,12]. 98 
 99 
In the present study we report clinical and genetic findings in two families with dominant 100 
OPA3-related optic neuropathy. The phenotypic spectrum of the disorder is broadened and 101 
intra- and inter-familial variability is discussed. 102 
 103 
 104 
MATERIALS & METHODS 105 
 106 
Initially, 74 unrelated individuals with a presumed diagnosis of inherited optic neuropathy 107 
(mean age 43 years; range 24 to 66 years) were tested for OPA3 mutations using Sanger 108 
sequencing of the three exons and flanking intron-exon boundaries of the OPA3 gene 109 
(primers and conditions available on request). All these subjects were previously screened 110 
and excluded for: (i) defects in the OPA1 gene ([MIM *605290]; the major cause of 111 
dominant optic neuropathy [2,13]) and (ii) the three primary mitochondrial mutations 112 
associated with Leber hereditary optic neuropathy ([MIM #535000]; m.11778G>A, 113 
m.14484T>C and m.3460G>A). Subsequently, members of an additional family with 114 
suspected dominant optic atrophy and cataracts were recruited and tested for OPA3 mutations 115 
in a similar fashion.  116 
 117 
Clinical assessment of individuals with OPA3-related disease included detailed history, best 118 
corrected Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity, dilated 119 
fundus examination and optic disc imaging. Optical coherence tomographs of the optic nerve 120 
head were obtained with the spectral-domain Cirrus platform (Carl Zeiss Meditec, Dublin, 121 
CA, USA) in two cases. An audiogram was performed in three patients. Informed consent 122 
was obtained from all participants and all investigations were conducted in accordance with 123 
the principles of the Declaration of Helsinki. Institutional Review Board (IRB)/Ethics 124 
Committee approval was obtained from the Multicentre Research Ethics Committee 125 
(MREC).  126 
 127 
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 128 
 129 
RESULTS 130 
 131 
Three OPA3 coding variants that have not been previously reported in publicly available 132 
databases (1000 genomes project database, National Heart, Lung, and Blood Institute Exome 133 
Sequencing Project or NHLBI ESP, dbSNP Build 139, accessed Jun 2014) were identified in 134 
the 180 amino acid isoform a (OPA3B; [NCBI Reference Sequence: NM_001017989.2]: 135 
c.227C>T, p.(Ala76Val); c.379G>A, p.(Gly127Ser) and c.389G>A, p.(Gly130Glu) 136 
(Supplementary Table S1). Each of these changes was detected in the heterozygous state in a 137 
simplex sporadic case and it was not possible to perform segregation analysis to support their 138 
pathogenicity. Also, none of these alters the amino acid sequence of isoform b (OPA3A) and 139 
wWe therefore, consider them to be variants of unknown significance. 140 
 141 
In addition to these variants, a heterozygous c.313C>G, p.(Gln105Glu) change (only 142 
affecting OPA3A, the transcript encoding the 179 amino acid isoform b; [NCBI Reference 143 
Sequence: NM_025136.3]) was identified in an individual with a diagnosis of dominant optic 144 
atrophy (subject C1; Figure 1A). This sequence alteration is the most common OPA3 145 
mutation associated with dominant disease as it was previously identified in four families 146 
segregating optic atrophy [9,10]; therefore no further evidence was needed to confirm that 147 
this is a functional variant. The proband as well as his affected sister (subject C2) and 148 
daughter (subject C3) presented in the first years of life with nystagmus and abnormal optic 149 
disc appearance. The clinical findings are detailed in Table 1. 150 
 151 
The same disease-associated variant, c.313C>G, p.(Gln105Glu), was detected in all three 152 
affected members of a family (Figure 1B) that were recruited and tested for OPA3 mutations 153 
at a later time. Colour disc images and clinical findings are presented in Figure 1C and Table 154 
1 respectively. 155 
 156 
 157 
DISCUSSION 158 
 159 
Dominant OPA3-related disease is a clinically heterogeneous disorder (Table 1); some 160 
patients present with poor visual behaviour and nystagmus from birth (for example subject 161 
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C1) while others remain asymptomatic until later in life (for example subject M2). The optic 162 
neuropathy is characterised by primary involvement of the papillomacular bundle and has 163 
similarities with that observed in individuals with OPA1 mutations [14]. Age of onset is in 164 
the first two decades of life (Table 1) and, although comprehensive longitudinal data are 165 
lacking, patients typically experience a slowly progressive, symmetrical decrease in vision 166 
[9,10]. Visual acuity is usually worse than 0.3 logMAR and it is of interest that one subject in 167 
the present series had preserved acuity and no visual complaints at age 41 (subject M2; 0.1 168 
logMAR right, 0.2 logMAR left; Table 1 and Figure 1D). Previous reports have shown that 169 
peripheral visual fields are spared and that colour vision is impaired [9,10]. Nevertheless, loss 170 
of colour discrimination is variable and without a systemic axis [10]. Subject M3 reported 171 
dyschromatopsia only in the right eye, in keeping with findings from colour vision testing 172 
with the Ishihara plates (right eye 4 of 17 plates; left eye 16 of 17 plates). 173 
 174 
On fundus examination, temporal optic disc pallor was the most common finding in the 175 
present cohort although diffuse pallor involving the whole neuroretinal rim and optic disc 176 
excavation are not unusual [9,10]. Notably, subject M1 was referred to the clinic after a 177 
routine eye test at age 60 revealed an enlarged cup-to-disc ratio (0.8) in the left eye (Figure 178 
1C); an erroneous initial diagnosis of glaucoma was made as consideration was not given to 179 
the fact that she had infantile-onset cataracts operated at age 35. Furthermore, subject M4 had 180 
a healthy optic disc appearance in the right eye and only subtle pallor in the left eye at age 14. 181 
In such equivocal cases measurement of retinal nerve fibre layer thickness with optical 182 
coherence tomography can be helpful (for example Figure 1D). Future imaging studies in 183 
patients with OPA3-related disease are expected to provide further insights.  184 
 185 
Crystalline lens opacities (i.e. cataracts) are observed in most affected individuals [9,10]. 186 
Nevertheless, a patient with a heterozygous p.(Val3_Gly4ins2) mutation and no cataracts at 187 
age 52 has been reported by Grau and colleagues [10]. Only one of the seven patients 188 
reported here had no clinical history of cataract: subject C3 was examined at age 38 and no 189 
lens opacity was detected. It is worth highlighting that a number of patients with OPA3-190 
related disease presented with bilateral lens opacities at birth or in early childhood (including 191 
subject M4 who was only noted to have optic atrophy after lens extraction at age 15); 192 
therefore, OPA3 mutations should be in the differential in cases of bilateral infantile-onset 193 
cataract and it is important to assess optic nerve function and health before concluding about 194 
the likely amblyogenicity of the lens opacities.  195 
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 196 
Ocular OPA3-related disease often occurs in parallel with extraocular clinical features. 197 
Reynier and colleagues reported affected members of a family with a heterozygous 198 
p.(Gly93Ser) change in OPA3 to have mild neurological signs including spasticity and 199 
extrapyramidal dysfunction [9]. Subsequently, Grau and colleagues reported four individuals 200 
with a heterozygous p.(Val3_Gly4ins2) change to have hearing loss. Expression analysis of 201 
OPA3 in murine cochlear tissue was consistent with the notion that auditory neuropathy can 202 
be an extraocular feature of OPA3-related disease [10]. Notably, two affected individuals 203 
from the present cohort had sensorineural hearing loss (Table 1); hearing impairment has 204 
been previously described in a patient with the same genetic defect [10]. Clinicians should be 205 
vigilant to the development of such a complication and audiograms should be performed in 206 
all patients with OPA3-related disease at least once. 207 
 208 
All OPA3 families with dominant disease reported to date have affected individuals in two or 209 
more generations and disease-associated variants appear to be highly penetrant (Figure 1A-B, 210 
[9,10]). The p.(Gln105Glu) change identified in both families reported here has been 211 
previously shown to be a recurrent mutation [10]; it was not possible to perform haplotype 212 
analysis in subjects from the present cohort and thus, the possibility of a recent common 213 
ancestor in the two families cannot be excluded. The p.(Gln105Glu) change affects an amino 214 
acid in a predicted coiled-coil structure (Uniprot) but it is unclear how this common cause of 215 
OPA3-related disease affects mitochondrial function and/or structure. 216 
 217 
Findings from this and other studies [9,10] suggest that dominant OPA3-related disease is 218 
associated with significant intra- and inter-familial phenotypic variability. Any attempt to 219 
draw genotype-phenotype correlations would therefore be highly speculative and secondary 220 
genetic factors are likely to be the basis for the observed clinical heterogeneity; a similar 221 
conclusion has been reached for the much commoner OPA1-associated optic neuropathy [14]. 222 
Expansion of the phenotypic spectrum of OPA3-related disease has led to greater 223 
understanding of the condition and the risks of developing extraocular complications. 224 
However, it is still unclear what disease mechanism explains multi-system tissue involvement 225 
and future studies on the pathogenesis of the disorder are expected to provide important 226 
insights. 227 
 228 
 229 
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TABLE 283 
 284 
Table 1. Clinical and genetic findings in subjects with dominant OPA3-related disease reported here and elsewhere. 
Subject 
(family ID) 
Age; 
sex 
VA 
(logMAR) Presentation/ 
onset Lens 
Heterozygous 
OPA3 change 
identified 
Other features 
right/left 
C1 
(GCC1) 72; M 1.30/1.30 
Nystagmus in 
infancy 
Blue-dot cataracts 
diagnosed at age 2 p.(Gln105Glu) - 
C2 
(GCC1) 62; F 1.00/1.00 
Nystagmus in 
infancy 
Cataracts operated 
at age 4 p.(Gln105Glu) - 
C3 
(GCC1) 38; F 0.80/0.80 
Nystagmus in 
infancy 
No significant lens 
opacity at age 38 p.(Gln105Glu) - 
M1 
(G43755) 65; F 0.72/1.04 
Cataracts at age 
34; re-referred 
as found by 
optometrist to 
have cupped left 
disc at age 60 
Cataracts operated 
at age 34; bilateral 
aphakia 
p.(Gln105Glu) 
Right mild-moderate 
s/n hearing loss; left 
moderate-severe s/n 
hearing loss; bilateral 
ocular hypertension on 
topical treatment 
M2 
(G43755) 41; M 0.10/0.20 
Mild cataracts at 
age 9; presently 
asymptomatic 
Nuclear cataracts 
operated at age 35 p.(Gln105Glu) 
Right and left mild-
moderate s/n hearing 
loss 
M3 
(G43755) 36; F 0.60/0.30 
Decrease in VA 
from age 19 
Blue-dot cataracts 
operated at age 
36&37 
p.(Gln105Glu) 
Normal audiogram; 
familial 
hypercholesterolaemia 
M4 
(G43755) 13; F 0.08/0.18 
Cataracts at age 
13 
Lamellar cataracts 
operated at age 15 p.(Gln105Glu) 
Congenital AV 
malformation in frontal 
lobe 
III.3 
(#1) [9] 38; F 0.70/0.70 
Poor vision 
from infancy 
Posterior cortical 
cataracts operated 
at age 51 
p.(Gly93Ser) 
Tremor of hands; 
extrapyramidal rigidity 
of upper limbs; absence 
of deep tendon reflexes 
IV.1 
(#1) [9] 15; F 0.30/0.30 
Decreased VA 
before age 10 
Posterior cortical 
cataracts operated 
at age 47&48 
p.(Gly93Ser) 
Mild postural tremor & 
mild rigidity of upper 
extremities 
IV.2 
(#1) [9] 57; F 0.60/0.50 
Decreased VA 
before age 10 
Anterior cortical 
cataracts operated 
at age 45&46 
p.(Gly93Ser) Postural tremor without 
extrapyramidal signs 
V.1 
(#1) [9] 29; F 0.70/0.52 
Decrease in VA 
from age 12 
Anterior cortical 
cataracts operated 
at age 25 
p.(Gly93Ser) Normal neurological 
examination 
VI.1 
(#1) [9] 4; F 0.15/0.15 
Visual 
impairment 
investigated at 
age 3 
Anterior & 
posterior cortical 
cataracts operated 
at age 4 
p.(Gly93Ser) Normal neurological 
examination 
IV.6 
(#1) [9] 50, F NA 
Visual 
impairment 
from infancy 
Cataracts p.(Gly93Ser) Normal neurological 
examination 
V.6 
(#1) [9] 5; F NA 
Visual 
impairment 
from infancy 
Cataracts operated 
at age 5 p.(Gly93Ser) 
Normal neurological 
examination 
III.3 
(#2) [9] 37; F 1.70/1.70 
Decrease in VA 
from age 12 
Posterior capsular 
cataract diagnosed 
at age 56 
p.(Gln105Glu) - 
III.7 
(#2) [9] 49; F 
“legally 
blind” 
Decrease in VA 
from age 10 
Cataracts diagnosed 
at age 45 p.(Gln105Glu) - 
IV.1 
(#2) [9] 33; F 1.30/1.30 
Decrease in VA 
from age 6 
Cataracts diagnosed 
at age 10; cerulean 
cataracts at age 33 
p.(Gln105Glu) Normal neurological 
examination 
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IV.2 
(#2) [9] 12; M 0.52/0.52 
Decreased VA 
at age 12 
Posterior capsular 
cataracts operated 
at age 19 
p.(Gln105Glu) - 
II.2 
(OAK1) [10] 57 1.00/1.00 
Diagnosed at 
age 18 Monocular cataract p.(Gln105Glu) - 
II.6 
(OAK1) [10] 54 0.40/0.50 Onset in infancy Cataracts p.(Gln105Glu) Hearing loss 
III.1 
(OAK1) [10] 35 0.52/0.30 Onset in infancy 
No significant lens 
opacity at age 19 p.(Gln105Glu) - 
III.2 
(OAK1) [10] 31 0.40/0.52 Onset in infancy Cataracts p.(Gln105Glu) - 
III.3 
(OAK1) [10] 17 0.52/0.40 Onset in infancy Cataracts p.(Gln105Glu) 
Chiari malformation 
type I 
I.1 
(OAK61) [10] 57 1.30/1.40 
Diagnosed at 
age 10 No information p.(Gln105Glu) - 
II.1 
(OAK61) [10] 33 0.40/0.40 
Diagnosed at 
age 19 
No significant lens 
opacity at age 25 p.(Gln105Glu) - 
II.4 
(OAK105)  [10] 84 1.15/1.30 Onset in infancy 
Congenital 
cataracts 
p.(Val3_Gly4ins
2) Hearing loss 
III.2 
(OAK105)  [10] 61 0.30/0.40 
Onset in 
adolescence 
No significant lens 
opacity at age 52 
p.(Val3_Gly4ins
2) Hearing loss 
III.3 
(OAK105)  [10] 62 0.52/0.40 
Diagnosed at 
age 19 Cataracts 
p.(Val3_Gly4ins
2) Hearing loss 
III.5 
(OAK105)  [10] 57 1.15/1.15 
Onset in 
adolescence 
Congenital 
cataracts 
p.(Val3_Gly4ins
2) Hearing loss 
IV.1 
(OAK105)  [10] 32 1.30/1.30 
Diagnosed at 
age 19 
Congenital 
cataracts 
p.(Val3_Gly4ins
2) Morbus Scheuermann 
III.1 
(OAK255)  [10] 46 NA Onset in infancy Cataracts p.(Gln105Glu) 
Intestinal pseudo-
obstruction 
III.2 
(OAK255)  [10] 47 NA Onset in infancy Cataracts p.(Gln105Glu) - 
F, female; M, male; VA, visual acuity; logMAR, logarithm of the minimum angle of resolution (equivalent); BE, both eyes; 
NA, not available; s/n, sensorineural; AV, arteriovenous. The term cataracts is used to denote bilateral crystalline lens 
opacities. Variants are annotated according to the NCBI Reference Sequence NM_025136.3 (OPA3 isoform b). 
 285 
286 
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FIGURE LEGEND 287 
 288 
Figure 1.  289 
A. Pedigree from a family segregating optic atrophy. Subjects C1 (IV:2), C2 (IV:5) and C3 290 
(V:3) had a heterozygous OPA3 change, c.313C>G, p.(Gln105Glu). 291 
B. Pedigree from a family segregating optic atrophy and cataracts. DNA from subjects M1 292 
(II:6), M2 (III:3) and M3 (III:4) was available for testing; a heterozygous c.313C>G, 293 
p.(Gln105Glu) change in OPA3 was identified in all there patients. See text and Table 1 for 294 
clinical findings of all tested individuals as well as subject M4 (IV:2).  295 
C. Right and left optic disc appearance of an individual with a confirmed OPA3 mutation 296 
(subject M1) showing pallor of the neuroretinal rim, which is more marked temporally. Left 297 
optic nerve appears more affected than the right and has optic disc excavation in addition to 298 
the temporal pallor. 299 
D. Left optic disc appearance and pattern of retinal nerve fibre layer (RNFL) thinning in an 300 
individual with a confirmed OPA3 mutation (subject M2). Sparing of the nasal, superior and 301 
inferior peripapillary quadrants is observed. The RNFL profile for each eye is superimposed 302 
on the normal distribution percentiles. The normal distribution indices are colour-coded: (i) 303 
red <1%, (ii) yellow <5%, (iii) green <95%, and (iv) white >95%. 304 
 305 
